spacer
home > pmps > winter 2001 > child-resistant clinical trials packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Child-Resistant Clinical Trials Packaging

Many pharmaceutical companies operating on a global basis are worried by the Consumer Product and Safety Commission's (CPSC) enforcement (which began on 23rd November 2000) of child-resistant packaging for clinical trials packs containing a potentially hazardous amount of drug, as part of America's Poison Prevention Packaging Act (PPPA). This could have a knock-on effect for the packaging of clinical trials in Europe with the recent introduction of the EU GCP Clinical Trials Directive, signed in December 2000 and to be implemented into member states legislation within two years.

Consumer groups in Europe are campaigning for standards for child resistance compliance to be brought more in line with the US protocol.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Colin Scaife, Managing Partner of C.E. Packaging Partnership
Colin Scaife formed C.E. Packaging Partnership to provide small and medium-sized pharmaceutical and health care companies with independent access to packaging development expertise and help in their understanding of legislation. He has over 30 years' experience of the packaging of pharmaceutical, health care and FMCGH products and is keen to promote innovative and practical packaging. He is Chairman of the joint ABPI/PAGB technical working party, monitoring packaging issues on behalf of the industry. He is also a recognised expert in the field of child-resistant packaging, being the Convenor of both the European and international standards committees, through which he drafts standards for the testing of child-resistant packaging.

spacer
Colin Scaife
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement